



For immediate release 14.00: 15 December 2015

HVIVO PLC
("hVIVO" or the "Company")

RESULT OF GENERAL MEETING

hVIVO plc (AIM: HVO), the pioneer of human challenge models of disease, is pleased to announce that the resolutions put to shareholders at today's General Meeting, in connection with the Placing announced by the Company on 26 November 2015, were duly passed.

Following the passing of the resolutions at the General Meeting, 9,111,111 new Ordinary Shares have been allotted to investors, conditional upon the admission of such Ordinary Shares to trading on AIM. It is expected that settlement will occur, admission to trading on AIM will become effective and dealings will commence in respect of the 9,111,111 new Ordinary Shares at 8.00am on 16 December 2015.

Following admission of the 9,111,111 new Ordinary Shares to trading on AIM, the total number of Ordinary Shares with voting rights in issue will be 78,052,784 and this figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the Financial Conduct Authority's Disclosure and Transparency Rules.

Upon admission, the new Ordinary Shares will be issued, credited as fully paid and will rank pari passu in all respects with the existing Ordinary Shares of the Company.

For further information please contact:

hVIVO plc

+44 207 756 1300

Kym Denny (Chief Executive Officer)
Graham Yeatman (Chief Financial & Business Officer)

Media Enquiries

+44 203 021 3933 / +44 7854 979 420

Colin Paterson (Director of Marketing, Communication and Public Relations)

Numis Securities Limited

+44 207 260 1000

Michael Meade / Freddie Barnfield (Nominated Adviser)
James Black / Michael Burke (Corporate Broking)

Notes to Editors:

hVIVO is a life sciences company pioneering a technology platform of human disease models to accelerate drug discovery and development in respiratory and infectious diseases.

Through its illumination of the entire disease life cycle from healthy to sick and back to health, the hVIVO platform captures disease in motion and promotes rational selection of drug targets and biomarkers in respiratory and infectious diseases, such as flu and colds. It brings together a revolutionary set of capabilities in product validation testing and the mining of biological insights, in order to tackle the long timeline, significant costs and high risks to market facing drug development and diagnostic organisations today.

A market leader in human disease models and challenge studies, hVIVO has commercialised four disease models, successfully enrolled over 2,000 subjects and conducted over 40 product validation studies for a wide range of industry, government and academia clients and collaborators.